Denied Ocrevus? You Still Have Options.
Ocrevus (ocrelizumab) is a targeted therapy for relapsing and primary progressive multiple sclerosis (MS), and it carries one of the higher prior authorization burdens of any MS medication. Insurers frequently deny Ocrevus when step therapy requirements haven't been met — meaning they want evidence you've tried other MS disease-modifying therapies first. Formulary restrictions and documentation gaps are also common reasons Ocrevus gets denied, even when it's the right clinical choice.
Option 1: Appeal Your Denial
Appeals for Ocrevus can succeed, especially with a compelling letter of medical necessity that explains why other MS therapies aren't appropriate for you and why ocrelizumab is the right clinical choice for your specific type of MS. Documentation of prior treatment failures, if applicable, significantly strengthens these arguments. Ellen can help you draft your appeal letter.
Option 2: Explore Clinical Trials
Ocrevus and other anti-CD20 therapies for multiple sclerosis are active areas of clinical research. Trials may study Ocrevus itself, biosimilars in development, or next-generation therapies in the same class. Participating may give you access to cutting-edge MS treatment at no cost. Search ClinicalTrials.gov for "ocrelizumab" or "multiple sclerosis" to see what's currently enrolling.
Option 3: Patient Assistance Programs
Genentech, the maker of Ocrevus, offers the Genentech Access Solutions program to help people who face coverage challenges or can't afford out-of-pocket costs. The National MS Society (nationalmssociety.org) also provides navigators and financial assistance resources specifically for people managing MS.
For a complete guide to Ocrevus financial assistance — including copay cards, free drug programs, and independent foundations — see our financial assistance page for Ocrevus.
Ellen can help you figure out your next step. Start with Ellen →
Frequently Asked Questions
Why was Ocrevus denied?
The most common reasons include step therapy requirements (the insurer wants documented evidence that you've tried approved first-line MS therapies first), missing or incomplete prior authorization, and sometimes disagreements about whether your specific MS diagnosis meets the plan's covered criteria. For primary progressive MS especially, coverage can be harder to secure since Ocrevus is one of very few approved options for that form of the disease. Your denial letter will include the specific reason, which shapes your appeal.
Can I get Ocrevus through a clinical trial?
Clinical trials studying ocrelizumab or closely related anti-CD20 therapies for MS do exist, and participants in approved trials typically receive the study medication at no cost. These trials aren't guaranteed to have open spots near you, and your eligibility depends on factors your doctor will need to review. Check ClinicalTrials.gov for currently enrolling studies and bring that information to your next appointment.
How long does an Ocrevus appeal take?
A standard internal appeal typically takes 30 days. Urgent appeals — when your doctor attests to medical urgency — must be decided within 72 hours. If your internal appeal is denied, you can escalate to an independent external review, which is generally resolved within 45 days. While you wait, your MS care team may have options for bridging your treatment. Talk to your doctor before making any decisions about your treatment.